More from Teva

To access this website you need to be a member of the healthcare profession because the materials included in this website are specifically prepared for that audience only.

Please click on the appropriate button below to confirm that you are a healthcare professional.

I am a healthcare professional I am not a healthcare professional



11.09.2019 - 13.09.2019 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

The Congress of the European Committee for Treatment and Research in Multiple Sclerosis was a unique opportunity to learn about many new developments in multiple sclerosis (MS). Areas covered included epidemiology, genetics, pathology, biomarkers, imaging, immunology and treatment.

ECTRIMS 2019 gave special attention to efficient treatment for progressive MS. The focus of the congress was on better understanding risk factors and mechanisms behind MS, as well as biomarkers, study design and novel treatment approaches.

The program offered scientific and educational sessions, plenary lectures, as well as “Hot Topic”, “Young Investigator” and poster sessions. “Hot Topics” at this year’s congress ranged from the diagnosis and treatment of MS to disease mechanisms, with some captivating issues being covered, including whether or not MS is becoming a milder disease, and when to stop or resume treatment during pregnancy. There were also insights into stem cell treatment, and epigenetics in MS pathogenesis and disease management.

ECTRIMS 2019 also featured an interactive debate on prescribing 1st generation injectables to newly diagnosed patients with active relapsing MS. Audience members could tweet their comments and questions during the presentations and vote for the winner at the end.

Scientific sessions covered a wide range of topics including “Socioeconomic outcomes in MS”, “Immunopathogenesis and antigen-specific therapies” and “Quantitative imaging biomarkers” amongst others.

Please click here to download the ECTRIMS 2019 report.

Download here